Redeye comments on IRLAB’s announcement of extended U.S. patent protection for mesdopetam, covering the salt form used in clinical development. This strategic milestone strengthens the candidate’s commercial potential by extending market exclusivity, potentially into the 2040s. Combined with recent regulatory progress, we believe that the new patent enhances IRLAB’s position in ongoing partnering discussions for mesdopetam ahead of phase III.
LÄS MER
